An exoskeleton developed by Harvard University researchers could restore multiple sclerosis patients’ balance and some of their walking capability, according to a study.
ReWalk Robotics is moving toward commercializing the ... Read more
Resistance training like weight lifting can protect or even regenerate the nerve cells of relapsing-remitting multiple sclerosis patients, slowing the progression of the disease, according to a clinical trial.
A ... Read more
The neurotransmitter glutamate triggers most brain signals by activating proteins on the surface of neurons called glutamate receptors.
Columbia University Medical Center researchers have taken the first 3D images of ... Read more
Eli Lilly and Nektar Therapeutics have established a development and commercial agreement for the investigational T-cell stimulator therapy NKTR-358 for the treatment of autoimmune disorders, including multiple sclerosis.
NKTR-358, discovered ... Read more
A new analysis of Phase 2 clinical data on Innate Immunotherapeutics’ investigational drug MIS416 to treat secondary progressive multiple sclerosis has confirmed that the drug failed to improve neuromuscular ... Read more
According to a study by researchers at Cleveland’s Case Western Reserve University School of Medicine, pre-existing inflammatory diseases affecting the central nervous system make mesenchymal stem cells less effective ... Read more
An Italian study shows that first-line treatment with Copaxone benefits relapsing-remitting multiple sclerosis patients by boosting the number of anti-inflammatory immune cells and restoring the balance of regulatory immune ... Read more
A herpes virus that lies dormant in many people can hinder the repair of the neuron-protecting myelin sheath whose deterioration causes multiple sclerosis, a study reports.
The finding about the ... Read more
A gene mutation may explain the uncontrolled, inflammatory immune response seen in autoimmune and chronic inflammatory diseases like multiple sclerosis, scientists at the Research Institute of the McGill University ... Read more
MSBase and icometrix have joined efforts in a large-scale project to identify imaging markers of multiple sclerosis (MS) that could help diagnose the disease in its early stages.
The combination ... Read more
Innate Immunotherapeutics’ MIS416 has failed to help secondary progressive multiple sclerosis (SPMS) patients in a Phase 2 clinical trial.
The company said it will continue testing the therapy, made up ... Read more
Merck’s cladribine tablets are now just one step away from obtaining European Union approval as a relapsing multiple sclerosis treatment. The European Medicines Agency’s Committee for Medicinal Products for Human ... Read more
Stephen L. Hauser, MD, director of the University of California, San Francisco (UCSF)‘s Weill Institute for Neurosciences, has been awarded the 2017 Taubman Prize for Excellence in Translational Medical Research. Recognized ... Read more
The U.S. Food and Drug Administration (FDA) has expanded approval of Dysport (abobotulinumtoxinA) for treatment of spasticity in adults, a condition that affects many people in the United States, ... Read more
Researchers at Cincinnati Children’s Hospital Medical Center (CCHMC) have developed a new experimental method to specifically target unwanted activation of the immune system without the toxicity of current immunoregulatory drugs. ... Read more
Researchers from the New York Stem Cell Foundation (NYSCF) have developed a method to produce brain immune cells, called microglia, from human stem cells. That can help scientists uncover biological mechanisms ... Read more
Relapsing multiple sclerosis (RMS) patients taking the investigational drug ozanimod, also known as RPC-1063, had lower relapse rate than those on weekly Avonex (interferon β-1a) therapy, according to Celgene in an announcement ... Read more
A real-world medical-facilities setting has confirmed clinical trial findings that Gilenya (fingolimod) can reduce multiple sclerosis relapses, according to a Spanish study published in Plos One. Gilenya, developed by Novartis Pharmaceuticals, was the first ... Read more
PODS (POlyhedrin Delivery System), a new technology designed to transport any protein in the human body, may open up new approaches in treating multiple sclerosis (MS) and other diseases, says ... Read more
A large-scale study revealed potential adverse reactions to beta-interferon (IFN-β) therapy, one of the most common treatments used for relapsing-remitting multiple sclerosis (RRMS). According to the study published in ... Read more
Laquinimod failed to meet its primary Phase 3 clinical trial objective of slowing the progression of relapsing-remitting multiple sclerosis (RRMS) after three months, according to its developers, Teva Pharmaceutical Industries and Active ... Read more
Smoking can kill off the immune cells that commonly protect people from multiple sclerosis (MS) and other autoimmune diseases, say researchers at the University of Copenhagen — a finding that may ... Read more
Neuroinflammation is an essential process in the development and progression of several neurodegenerative diseases, including multiple sclerosis (MS), Alzheimer’s and Parkinson’s. Researchers from the University of North Carolina School ... Read more
Greek researchers have developed a new bioinformatics tool to identify potential therapies for chronic inflammatory diseases. Using this approach, they identified and confirmed the therapeutic potential of two small molecules ... Read more
Many decisions to stop taking the multiple sclerosis treatment Tysabri (natalizumab) appear to be based largely on subjective factors such as patients’ or physicians’ view of the risk, rather than objective assessments ... Read more
The latest results on Tecfidera (dimethyl fumarate) and Tysabri (natalizumab) use in a clinical practice setting suggest that early treatment can improve outcomes in multiple sclerosis (MS) patients. This and ... Read more
The United Kingdom’s National Institute for Health and Care Excellence (NICE) last month recommended Zinbryta (daclizumab) to treat relapsing-remitting multiple sclerosis (RRMS) in England and Wales. On April 10, Scotland received Scottish Medicines Consortium (SMC) approval for ... Read more
The effect air and noise pollution can have on the development of neurodegenerative diseases is not fully understood, but results from a large study published in The Lancet suggest living ... Read more
Compugen has reported new and promising results from studies on animal models of multiple sclerosis (MS) that support its lead drug candidate, CGEN-15001, as a potential treatment for a variety of autoimmune diseases, ... Read more
Alterations in microorganisms in the brains of multiple sclerosis (MS) patients could contribute to underlying disease mechanisms, including demyelination, according to researchers. The study, “Brain microbiota disruption within inflammatory ... Read more
A recent study published in Nature Communications showed, for the first time, that a protein complex called LUBAC is responsible for controlling the late-stage development of immune T-cells before they ... Read more
People with late-onset multiple sclerosis (MS) tend to more rapidly rise in disability scores than younger patients with early onset MS, according to study in MS patients in Kuwait that compared ... Read more
Multiple sclerosis (MS) patients with more advanced disease, as evidenced by disability, and those more frequent relapses or aversion to needles are among the groups of people at higher risk ... Read more
A study published in the BMC Neurology journal emphasized that clear and regular communication between physicians and patients with multiple sclerosis (MS) is essential for patient satisfaction with a given treatment, ... Read more